|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PALM2 |
Gene summary for PALM2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PALM2 | Gene ID | 445815 |
| Gene name | PALM2 and AKAP2 fusion | |
| Gene Alias | AKAP-2 | |
| Cytomap | 9q31.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q9Y2D5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 445815 | PALM2 | HCC1_Meng | Human | Liver | HCC | 2.06e-03 | 2.10e-03 | 0.0246 |
| 445815 | PALM2 | HCC1 | Human | Liver | HCC | 5.72e-09 | 1.46e+00 | 0.5336 |
| 445815 | PALM2 | HCC2 | Human | Liver | HCC | 6.25e-19 | 2.57e+00 | 0.5341 |
| 445815 | PALM2 | HCC5 | Human | Liver | HCC | 5.16e-18 | 1.77e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Esophagus | ESCC |  |
| Skin | AK |  |
| Skin | SCCIS |  |
| Skin | cSCC |  |
| Thyroid | HT |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PALM2 | SNV | Missense_Mutation | c.556N>G | p.Leu186Val | p.L186V | Q8IXS6 | protein_coding | tolerated(0.07) | benign(0.015) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
| PALM2 | SNV | Missense_Mutation | rs777919306 | c.658G>A | p.Val220Ile | p.V220I | Q8IXS6 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-B6-A0RU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| PALM2 | SNV | Missense_Mutation | rs140454806 | c.895G>A | p.Ala299Thr | p.A299T | Q8IXS6 | protein_coding | tolerated(0.71) | benign(0) | TCGA-ZJ-AAXN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| PALM2 | SNV | Missense_Mutation | rs776820674 | c.1181N>G | p.Glu394Gly | p.E394G | Q8IXS6 | protein_coding | deleterious(0.05) | benign(0.197) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| PALM2 | SNV | Missense_Mutation | novel | c.1220N>A | p.Cys407Tyr | p.C407Y | Q8IXS6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PALM2 | SNV | Missense_Mutation | c.845N>T | p.Arg282Met | p.R282M | Q8IXS6 | protein_coding | tolerated(0.14) | possibly_damaging(0.579) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PALM2 | SNV | Missense_Mutation | rs780970261 | c.644N>A | p.Arg215His | p.R215H | Q8IXS6 | protein_coding | tolerated(1) | benign(0) | TCGA-NH-A50T-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PALM2 | SNV | Missense_Mutation | c.730N>G | p.Ser244Gly | p.S244G | Q8IXS6 | protein_coding | tolerated(0.1) | benign(0.02) | TCGA-AG-A036-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| PALM2 | SNV | Missense_Mutation | c.932N>T | p.Thr311Ile | p.T311I | Q8IXS6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PALM2 | SNV | Missense_Mutation | rs749416916 | c.1070N>T | p.Thr357Met | p.T357M | Q8IXS6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |